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Sophie Paczesny,1 John E . Levine,1,2 Thomas M. Braun,3 James L. M. Ferrara1,2Acute graft versus host disease (GVHD) remains a major complication of allogeneic hematopoietic cell trans-
plantation (HCT). The diagnosis of acute GVHD is based on strictly clinical criteria and its severity also de-
termined by these criteria. Currently, there is no validated diagnostic blood test for acute GVHD. This
review will summarize proteomics approaches to identify biomarkers for GVHD in the plasmawith diagnostic,
prognostic and predictive value. If successful, these studies could establish a novel biomarker panel that will
contribute important information including long term survival, and that may eventually facilitate therapeutic
decisions for allogeneic HCT patients.
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The diagnosis of acute graft-versus-host disease
(GVHD) is based on clinical criteria that may be con-
firmed by biopsy of 1 of the 3 target organs (skin, gas-
trointestinal tract, or liver). The severity of acute
GVHD is graded clinically from I to IV using a stan-
dardized system that evaluates 3 principal target or-
gans [1], with increased mortality rates associated
with significant GVHD (grades II-IV) [2].
There is no validated diagnostic blood test for
acute GVHD, although small studies have identified
multiple blood proteins as potential biomarkers [3-
23]. Differences in any single protein lack sufficient
specificity and sensitivity to be of clinical use, however.
Although recent mass spectrometry (MS) profiling of
urine [24,25] and serum [26] has found spectral pat-
terns associated with GVHD, these approaches do
not identify specific proteins. We previously reported
a quantitative analysis of a number of potential bio-
markers for GVHD in the plasma of a small number
of patients [27]. To date, however, no study has devel-
oped a simple noninvasive test that indicatesGVHD in
a sufficient number of patient samples that would allowDepartments of Pediatrics; 2Internal Medicine; and 3Bio-
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The complex pathophysiology of GVHD [28] sug-
gests that plasma proteins involved in multiple pro-
cesses (eg, T cell alloreactivity, inflammation, tissue
damage and repair) might be altered in patients with
the disease. Furthermore, the dynamic nature of the
circulatory system and the ease of blood sampling
make blood a logical choice for biomarker applica-
tions. Blood components include various cellular ele-
ments, such as immunologic cells, leukemic cells,
cell-free DNA and RNA, proteins, peptides, and me-
tabolites. Proteins that are detectable in plasma or se-
rum form the basis of common tests to screen and
monitor several cancers, including prostate-specific
antigen for prostate cancer and Ca125 for ovarian can-
cer. The goal of having such biomarker in the blood for
the diagnostic and prognostic of acute GVHD has not
yet been achieved.ONE PROTEOMICS DISCOVERYAPPROACH
Experimental design plays a crucial role in a suc-
cessful biomarker search. The first step in this design
is to choose the most informative specimens and
achieve adequate matching between cases and controls
to avoid bias. This goal is best achieved through a data-
base containing high-quality samples linked to quality-
controlled clinical information. We started a reposi-
tory at the University of Michigan in 2000 that cur-
rently contains approximately 8000 samples from 850
individuals. Blood was drawn at approximately weekly
intervals in the first 2 months after hematopoietic cell
transplantation. We analyzed these samples using an33
Figure 1. Antibody array heatmap of discovery set samples. This heatmap depicts relative protein values obtained from antibody microarrays after the
removal of batch effects due to 3 separate analyses. Samples from 21 GVHD– patients (A) and 21 GVHD1 patients (B) are represented. Only the an-
tibodies giving the 35 smallest P values for differences between GVHD1 and GVHD– patient plasma are shown. The P values compare the GVHD1 and
GVHD– samples. (Reproduced with permission [29].)
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120 human proteins that targeted diverse classes of
proteins, including acute-phase reactants, cytokines,
angiogenic factors, tumor markers, leukocyte adhesion
molecules, and metalloproteinases and their inhibi-
tors. We hypothesized that samples from patients
with severe GVHDwould bemost likely to yield infor-
mative biomarkers.
We first performed a discovery study that com-
pared samples from 21 patients with severe acute
GVHD (GVHD1severe) with samples from 21 patients
without GVHD who were similar in age, intensity of
conditioning regimen (reduced vs full), donor source
(related vs unrelated), and time of sample acquisition.
Figure 1 shows the 35 biomarkers that exhibited the
greatest differences between the 2 groups [29].VALIDATION STRATEGIES FOR DISCOVERED
PROTEIN BIOMARKERS
For any biomarker, the path from discovery to ap-
proval for clinical use is arduous. The biomarker vali-
dation process is long and involves several steps
(although it is more direct than the discovery step).
Validation studies have obstacles of their own. Most
noteworthy of these is the paucity of affinity-capture
agents, such as high-quality antibodies with the re-quired affinity and specificity for the target. The num-
ber of samples required for validation also increases as
the biomarker advances though the phases, hence the
need for high-throughput assays. The most relied-on
approach for validation remains the sandwich en-
zyme-linked immunosorbent assay (ELISA), which is
highly specific, with a pair of antibodies used against
the candidate protein. In our study, we used a sequen-
tial ELISA protocol to maximize the number of mea-
sured analytes per sample. This sequential protocol
measures multiple analytes per plasma sample by reus-
ing the same aliquot consecutively in individual ELISA
plates.
Another level of validation involves using a statisti-
cal validation set, a portion of the data set used to assess
the performance of classification or prediction models
that have been fit on a separate portion of the same data
set (the training set). Both the training and validation
sets are randomly selected, with the validation set pro-
viding a more objective measure of the performance of
various models that are fit to the training data.RATIONALDESIGNOFBIOMARKERS PANELS
FOR GVHD DIAGNOSIS
Single biomarkers clearly lack the required sensi-
tivity and specificity for most clinical applications.
Figure 2. ROC curves of 4 individual discriminator proteins and the
composite panel in the training set. Individual ROC curves for IL-2Ra,
TNFR1, HGF, and IL-8 and the composite panel. (Reproduced with per-
mission [29]).
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ceiver operating characteristic (ROC) curve, a plot of
the false-positive rate on the x axis and the true-posi-
tive rate on the y axis for every possible level of
a marker. A perfect test would have a ROC curve ap-
pearing as a right angle, demonstrating 100% of true
positives and no false positives. In this case, the corre-
sponding area under the curve (AUC) will equal 1. A
random test will have an AUC of 0.5, meaning 1 false
positive for every 1 true positive. A biomarker panel
might include a candidate biomarker that otherwise
may be dismissed if it provides only modest sensitivity
in initial studies. This biomarker may be valuable if it is
informative with respect to a particular subset of sub-
jects. For example, in our study, logistic regression
models determined that a linear combination of values
for interleukin (IL)-2Ra, tumor necrosis factor recep-
tor 1 (TNFR1), hepatocyte growth factor (HGF), and
IL-8 produced the best model for predicting the oc-Figure 3. Low-risk and high-risk groups correlated with GVHD grade. The blu
high-risk groups, in the training (A) and validation (B) sets. The solid blue repcurrence of acute GVHD. Figure 2 shows the ROC
curves of these 4 biomarkers and the composite bio-
marker panel, with an AUC for the composite bio-
marker panel of 0.91 (95% confidence interval [CI]
5 0.87 to 0.94). Levels of IL-2Ra and TNFR1 con-
tributed primarily to the model’s accuracy (P\ .001
and P 5 .003, respectively). When logistic regression
models were used to determine whether the 4 bio-
marker panel provided prognostic information, HGF
was the only marker that predicted maximum
GVHD grade (P 5 .003), and both HGF and IL-
2Ra were associated with specific target organs (P 5
.03 and .04, respectively).CLINICAL APPLICATIONS
Physicians are interested in low-risk and high-risk
groups for predicting the development of GVHD and
clinical outcomes. In the present study, we divided the
patients in the training set into a high-risk group and
a low-risk group based on their predicted probability
for developing GVHD. We determined the threshold
for high so that the false-positive rate did not exceed
5%. We then investigated whether the 4- biomarker
panel described above provided prognostic informa-
tion regarding the eventual maximum grade of
GVHD and nonrelapse mortality (NRM) and overall
survival (OS).
In the training set, the low-risk group consisted
primarily of patients with grade 0 GVHD, as shown
in Figure 3A; only a few patients had GVHD grade
I-IV. In the high-risk group,\ 10% of patients had
GVHD grade 0, and most patients had GVHD grade
I-IV. Importantly, the results were very similar in the
validation set, where the model predicted the GVHD
grades of the patients without knowledge of their clin-
ical symptoms (Figure 3B).
Figure 4 shows the NRM and OS for the low-risk
and high-risk groups. When adjusted for age, donor
type, HLA match, and intensity of conditioning, thee boxes represent the low-risk groups, and the red boxes represent the
resents GVHD grade 0; the solid red, GVHD grade I-IV.
Figure 4. NRM and OS stratified by the biomarker panel in the training set (A) and validation set (B). In (A), the cumulative incidence of NRM and OS
(determined by Kaplan-Meier) are plotted according to the predicted probability of acute GVHD: low (—; n5 193) and high (—; n5 89) (P5 .001 and
.006, adjusted for age, donor type, HLA match, and intensity of conditioning, for differences in NRM and OS, respectively). NRM at 3.5 years is 15% (95%
CI5 9% to 21%) for the low-risk group and 36% (95% CI5 24% to 48%) for the high-risk group. OS at 3.5 years is 53% (95% CI5 45% to 63%) for the
low-risk group and 33% (95% CI5 22% to 48%) for the high-risk group. In (B), the cumulative incidence of NRM and OS of the 2 groups are plotted for
the validation set: low (—; n5 93) and high (—; n5 49) (P\.001 and .02, adjusted as before, for differences in NRM and OS, respectively). NRM at 3.5
years is 11% (95% CI5 4% to 19%) for the low-risk group and 38% (95% CI5 23% to 53%) for the high-risk group. OS at 3.5 years is 59% (95% CI5 49%
to 72%) for the low-risk group and 44% (95% CI 5 31% to 63%) for the high-risk group. (Reproduced with permission [29].)
36 Biol Blood Marrow Transplant 15:33-38, 2009S. Paczesny et al.differences in NRM between the 2 groups were highly
significant (P5 .001; Figure 4A).When we applied the
same definition to the validation set, the false-positive
rate in the high-risk group was 6%. The NRM be-
tween groups was again significantly different when
adjusted for all 4 variables (Figure 4B; P \ .001).
The 2 groups also experienced significantly different
OS in both the training set (Figure 4A; P 5 .006, ad-
justed) and validation set (Figure 4B; P 5 .02, ad-
justed).Figure 5. Intact protein analysis system workflow and in-depth analysis
of plasma proteins. Plasma pooled from 10 patients with GVHD was la-
beled with the heavy isotope and compared with plasma pooled from 10
patients with no GVHD labeled with the light isotope. The specimens
were then subjected to extensive fractionation (by ion-exchange chro-
matography and reverse-phase chromatography) before individual frac-
tions were analyzed. This decreased the complexity of individual
fractions subjected to analysis by liquid chromatography-MS/MS. (Adap-
ted from [30].)A SECOND PROTEOMICS APPROACH FOR
TARGETORGAN–SPECIFIC BIOMARKERS
Studies of the use of various mass spectrometry
(MS)-based proteomic approaches to diagnose
GVHD have produced promising results [24-26]. An
advantage of these approaches is that identification of
proteins does not depend on the availability of anti-
bodies, as is the case when using microarrays. These
MS-based techniques do have some inherent disadvan-
tages, including inability to identify specific proteins,
labor-intensity, lack of speed, and limited sensitivity
for proteins present at low levels. Newer technologies,
such as tandem MS (MS/MS), make these approaches
more attractive. Given the low abundance of known
individual GVHD markers in serum and plasma, the
issue is whether current proteomic technologies pro-
vide sufficient depth of analysis for novel biomarker
discovery. Three studies using current MS/MS tech-
nologies have identified proteins in low concentrations
in plasma [30-32].
No plasma biomarkers are specific to any of the 3
target organs of acute GVHD: skin, gastrointestinal(GI) tract, or liver. We sought to identify a biomarker
that is specific for GVHD of the skin (sGVHD) in an
initial discovery step using an intact proteomic analysis
system (Figure 5). We compared plasma pooled from
10 patients with sGVHD only, plasma pooled from
Biol Blood Marrow Transplant 15:33-38, 2009 37Plasma Biomarkers in GVHD10 patients with no GVHD, and plasma pooled from
10 patients with GVHD of the GI tract only. Of the
4 candidate proteins that were both significantly ele-
vated only in the plasma of the sGVHD patients and
could be measured by ELISA, we selected elafin, an
epidermal proteinase inhibitor that is induced by
TNF-a and found in inflamed epidermis in such dis-
eases as psoriasis. We measured levels of elafin in indi-
vidual samples of the discovery set and found that they
were significantly higher in the samples from the pa-
tients with sGVHD compared with the samples from
the patients with GI GVHD and without GVHD.
We also analyzed a validation set of. 400 plasma sam-
ples from patients who had undergone allogeneic bone
marrow transplantation at the University of Michigan.
Elafin levels in the plasma from the patients with
sGVHD were double those in the plasma from the pa-
tients without GVHD.
We next explored whether elafin level can provide
prognostic information regarding the eventual maxi-
mum stage of sGVHD, transplantation-related mor-
tality (TRM), and OS. For this purpose, we divided
the patients into 2 groups, using a threshold level of
elafin that provided 85% specificity. The group with
the high elafin levels developed more severe sGVHD
(maximum stage), higher TRM at 1 year, and lower
OS at 1 year compared with the group with low elafin
levels. Our findings suggest that a biomarker such as
elafin that is specific for a target organ (skin) can be dis-
covered and validated and can provide important diag-
nostic and prognostic information that eventually
could be useful in modifying our therapeutic options.ACKNOWLEDGMENTS
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